Latest:
Dr Ahn on Outcomes With Ovarian Function Suppression in HER2+ Breast Cancer
Sung Gwe Ahn, MD, PhD, discusses an exploratory analysis of ovarian function suppression in patients with HR-positive, HER2-positive breast cancer.
Authors
Peter Riedell, MD
Peter Riedell, MD, is an associate professor of medicine in the Section of Hematology/Oncology at the University of Chicago.
Latest:
Overcoming Barriers and Improving CAR T Care in Academic and Community Settings
Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.
Mridula George, MD
Latest:
Dr. George on the Risk of Cardiotoxicity with Adjuvant T-DM1 Plus Radiotherapy in HER2+ Breast Cancer
Mridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.
Ali Amjad, MD
Latest:
FDA Approvals of Immunotherapy in Gynecology Oncology
In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.
Balazs Halmos, MD, MS
Balazs Halmos, MD, is the director of Thoracic Oncology and the director of Clinical Cancer Genomics at Albert Einstein College of Medicine, Montefiore Einstein
Latest:
Lung Cancer Experts Highlight the Significance and Limitations of ADCs
Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.
Martin Reck, MD, PhD
Latest:
Five-Year Outcomes With First-Line (1L) Nivolumab + Ipilimumab + Chemotherapy (N + I + C) vs C in Patients (pts) With Metastatic NSCLC (mNSCLC) in CheckMate 9LA
Dr. Martin Reck presents the five year update of CheckMate 9LA (NCT03215706) and exploratory analysis of efficacy in patients who discontinued treatment due to treatment related adverse events in patients with metastatic non-small lung cancer.
Jacqueline Barrientos, MD, MS
Latest:
Expert Insights into Investigation Therapies for CLL
Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.
Olalekan O. Oluwole, MD, MPH
Olalekan Oluwole, MD, MPH, is an associate professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center.
Latest:
Dr Oluwole on the Importance of Assessing the Onset and Incidence of Axi-Cel–Related Neurotoxicity in R/R DLBCL
Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.